个人简历

教育背景
2000/09–2003/07，郑州大学，医学院，学士
2003/09–2006/07，郑州大学，第二临床医院，硕士
2013/09-2016/07，天津医科大学，基础医学院，博士
工作经历
2013/09–至今， 天津医科大学，基础医学院，讲师
2006/07-2013/08， 天津医科大学，基础医学院，助教
荣誉奖励
2012年，天津医科大学科技成果奖。骨肉瘤中WWOX基因的分子遗传学研究（津医KG-11005-01）。杨吉龙，杜晓玲，张瑾，潘毅，冯玉梅
2014年，中国抗癌协会科技奖三等奖。应用遗传组学方法筛选常见肉瘤的生物标记及治疗靶点（K-1303-3-15）杨吉龙,赵军,杜晓玲,杨蕴,郑红
2015年，天津市科技进步奖三等奖应用遗传组学方法筛选常见肉瘤的生物标记物及治疗靶点（2015JB-3-126-R1）。杨吉龙，杜晓玲，陈可欣，王国文，朱泽

研究领域

肿瘤遗传不稳定性

近期论文

1.常方圆，杜晓玲 ， 李锋 ， 李婷 ， 杨吉龙*。T-box蛋白质2在肿瘤中的作用及转化研究进展。中华实验外科杂志 , 2018 (2)：370-374
2.Rashi Bharat Pate, Ting L, Zhichao Liao, Jivani Aakash Jaldeepbha, HA Pavanika NV Perer, Sujani Kaushalya Muthukud, Dholiya Hardeep Dhirubha , Vaibhav Sing, Xiaoling Du, Jilong Yang*. Recent translational research into targeted therapy for liposarcoma. Stem cell investigation, Stem Cell Investig. 2017 Mar 15;4:21.
3.Feng Li, Zhichao Liao, Jun Zhao, Gang Zhao, Xubin Li, Xiaoling Du, Yun Yang, Jilong Yang*. Efficacy and safety of Apatinib in stage IV sarcomas: experience of a major sarcoma center in China. Oncotarget. 2017 Mar 16;8(38):64471-64480.
4.Du X, Yang J*, Yang D, Tian W, Zhu Z*. The genetic basis for inactivation of Wnt pathway in human osteosarcoma. BMC Cancer 2014, 14:450.
5.Du X, Yang J*, Ylipaa A, Zhu Z*. Genomic amplification and high expression of EGFR are key targetable oncogenic events in malignant peripheral nerve sheath tumor. J Hematol Oncol 2013, 6:93.
6.Fangyuan Chang, Peipei Xing, Fengju Song, Xiaoling Du, Guowen Wang, Kexin Chen, Jilong Yang*. The roles of TBXs in the tumorigenesis and progression of varied cancers. Oncology reports, 2016 Dec;12(6):4305-4311.
7.Zhou W, Du X, Song F, Zheng H, Chen K, Zhang W, Yang J*. Prognostic roles for fibroblast growth factor receptor family members in malignant peripheral nerve sheath tumor. Oncotarget. 2016 Apr 19;7(16):22234-44.
8.Hao M, Zhao G, Du X, Yang Y, Yang J*. Clinical characteristics and prognostic indicators for metastatic melanoma: data from 446 patients in north China. Tumor Biol. 2016 Aug;37(8):10339-48.
9.Wenyan Zhou, Hong Zheng, Xiaoling Du, Jilong Yang*. Charaterization of FGFR signaling pathway as therapeutic targets for sarcoma patients. Cancer Biol Med, 2016,13,260-268
10.Hao M, Song F, Du X, Wang G, Yang Y, Chen K, Yang J*. Advances in targeted therapy for unresectable melanoma: New drugs and combinations. Cancer Lett. 2015;359(1):1-8.
11.周文雅，王国文，郝梦泽，杜晓玲，杨蕴，杨吉龙*. 骨肉瘤重要信号通路的遗传学研究。中华骨科杂志，2015，35（2）1-8.
12.杨吉龙*，杜晓玲，王国文，杨蕴. 恶性间叶肿瘤的间叶-上皮表型转化研究进展. 中国肿癌临床 2014, 41(24):56-60.
13.Zhou W, Hao M, Du X, Chen K, Wang G, Yang J*. Advances in targeted therapy for osteosarcoma. Discov Med 2014, 17(96):301-307.
14.Yang J*, Ren Z, Du X, Zhou W, Hao M. The role of mesenchymal stem/progenitor cells in sarcoma: update and dispute. Stem Cell Investigation 2014, 1(18):1-9.
15.Yang J*, Du X, Wang G, Sun Y, Chen K, Zhu X, Lazar AJ, Hunt KK, Pollock RE, Zhang W*. Mesenchymal to epithelial transition in sarcomas. Eur J Cancer 2014, 50(3):593-601.
16.Yang J*, Annala M, Ji P, Wang G, Zheng H, Codgell D, Du X, Fang Z, Sun B, Nykter M, Wei Zhang*. Recurrent LRP1-SNRNP25 and KCNMB4-CCND3 fusion genes promote tumor cell motility in human osteosarcoma. J Hematol Oncol 2014, 7(1):76.
17.Hao MZ, Zhou WY, Du XL, Chen KX, Wang GW, Yang Y, Yang JL*. Novel anti-melanoma treatment: focus on immunotherapy. Chin J Cancer 2014, 33(9):458-465.
18.Yang J*, Du X. Genomic and molecular aberrations in malignant peripheral nerve sheath tumor and their roles in personalized target therapy. Surgical oncology 2013, 22(3):e53-57.
19.邢汝维,杜晓玲,杨吉龙*,潘毅,宋金纲,王坚,朱雄增. 肾脏癌肉瘤伴发肺腺癌1例. 中国肿瘤临床 2010(24):1423-1424+1431.
20.Yang J, Yang D, Cogdell D, Du X, Li H, Pang Y, Sun Y, Hu L, Sun B, Trent J, Zhang W*. APEX1 gene amplification and its protein overexpression in osteosarcoma: correlation with recurrence, metastasis, and survival. Technol Cancer Res Treat 2010, 9(2):161-169.